Comparison of Neurotrope Inc. (NTRP) and Ionis Pharmaceuticals Inc. (NASDAQ:IONS)

As Biotechnology businesses, Neurotrope Inc. (NASDAQ:NTRP) and Ionis Pharmaceuticals Inc. (NASDAQ:IONS), are affected by compare. This especially applies to their profitability, analyst recommendations, risk, dividends, earnings and valuation, institutional ownership.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Neurotrope Inc. N/A 0.00 11.02M -1.47 0.00
Ionis Pharmaceuticals Inc. 599.67M 19.46 276.87M 0.51 137.95

In table 1 we can see Neurotrope Inc. and Ionis Pharmaceuticals Inc.’s gross revenue, earnings per share (EPS) and valuation.


Table 2 provides Neurotrope Inc. and Ionis Pharmaceuticals Inc.’s return on equity, return on assets and net margins.

Net Margins Return on Equity Return on Assets
Neurotrope Inc. 0.00% -93.4% -84%
Ionis Pharmaceuticals Inc. 46.17% -31.1% -8.7%

Volatility & Risk

Neurotrope Inc. has a 2.83 beta, while its volatility is 183.00%, thus making it more volatile than S&P 500. Competitively, Ionis Pharmaceuticals Inc.’s 139.00% volatility makes it more volatile than S&P 500, because of the 2.39 beta.


The current Quick Ratio of Neurotrope Inc. is 6.4 while its Current Ratio is 6.4. Meanwhile, Ionis Pharmaceuticals Inc. has a Current Ratio of 8 while its Quick Ratio is 8. Ionis Pharmaceuticals Inc. is better positioned to pay off its short-term and long-term debts than Neurotrope Inc.

Analyst Ratings

The Ratings and Recommendations for Neurotrope Inc. and Ionis Pharmaceuticals Inc. are featured in the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Neurotrope Inc. 0 0 0 0.00
Ionis Pharmaceuticals Inc. 0 2 1 2.33

Ionis Pharmaceuticals Inc. on the other hand boasts of a $68.33 average target price and a -18.94% potential downside.

Insider & Institutional Ownership

Neurotrope Inc. and Ionis Pharmaceuticals Inc. has shares owned by institutional investors as follows: 26.8% and 89.1%. 25.36% are Neurotrope Inc.’s share owned by insiders. Competitively, 0.2% are Ionis Pharmaceuticals Inc.’s share owned by insiders.


In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Neurotrope Inc. -15.67% 2.83% -26.97% -51.72% -49.24% 22.13%
Ionis Pharmaceuticals Inc. 14.3% 21.53% 21.62% 52.61% 33.45% 30.39%

For the past year Neurotrope Inc. was less bullish than Ionis Pharmaceuticals Inc.


Ionis Pharmaceuticals Inc. beats on 11 of the 11 factors Neurotrope Inc.

Neurotrope, Inc., a biopharmaceutical company, focuses on developing therapeutic and diagnostic technologies in the field of neurodegenerative diseases in the United States. The companyÂ’s lead product candidate is bryostatin-1, a natural product isolated from a marine invertebrate organism, which is in a Phase II trial for the treatment of moderate to severe AlzheimerÂ’s dementia, as well as in preclinical studies as a treatment for Fragile X Syndrome, Niemann-Pick Type C disease, and Rett Syndrome. It has a license agreement with the Leland Stanford Junior University to sublicense Bryologs that are structural derivatives of Bryostatin for use in the treatment of central nervous system disorders, lysosomal storage diseases, stroke, cardioprotection, and traumatic brain injury; and technology license and services agreement with Cognitive Research Enterprises, Inc. and its affiliate, NRV II, LLC. The company was founded in 2012 and is based in New York, New York.

Ionis Pharmaceuticals, Inc. engages in discovering and developing RNA-targeted therapeutics. The company markets SPINRAZA, an antisense drug for spinal muscular atrophy in pediatric and adult patients; and Kynamro an oligonucleotide inhibitor for use in patients with homozygous familial hypercholesterolemia to reduce low density lipoprotein-cholesterol, apolipoprotein B, total cholesterol, and non-high density lipoprotein-cholesterol, and as an adjunct to lipid lowering medications and diet. Its drugs in Phase III development include volanesorsen for the treatment of patients with familial chylomicronemia syndrome and familial partial lipodystrophy; and IONIS-TTRRx, an antisense drug to treat all forms of transthyretin amyloidosis. The company also develops IONIS-HTTRx, an antisense drug to treat patients with Huntington's disease; IONIS-SOD1Rx, an antisense drug to treat patients with an inherited form of amyotrophic lateral sclerosis; AKCEA-ANGPTL3-LRx, a LICA drug for treating multiple lipid disorders or mixed dyslipidemias; IONIS-PKKRx, an antisense drug that treats patients with hereditary angioedema; IONIS-FXIRx, an antisense drug for the treatment of thrombosis; AKCEA-APO(a)-LRx, a LICA drug that reduces apolipoprotein(a) in the liver to offer a direct approach for reducing lipoprotein(a); and AKCEA-APOCIII-LRx, an antisense drug for cardiometabolic disease. In addition, it develops IONIS-AR-2.5Rx, an antisense drug that treats patients with prostate cancer; IONIS-STAT3-2.5Rx, a cancer drug; AKCEA-ANGPTL3-LRx, a LICA drug to treat multiple lipid disorders; IONIS-GCGRRx, an antisense drug to treat patients with type 2 diabetes; and IONIS-DGAT2Rx, an antisense drug to treat patients with liver disease. The company was formerly known as Isis Pharmaceuticals, Inc. and changed its name to Ionis Pharmaceuticals, Inc. in December 2015. Ionis Pharmaceuticals, Inc. was founded in 1989 and is headquartered in Carlsbad, California.